Federated Hermes Inc. Has $126,000 Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Federated Hermes Inc. lessened its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 99.0% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 4,500 shares of the company’s stock after selling 463,800 shares during the period. Federated Hermes Inc.’s holdings in Structure Therapeutics were worth $126,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of GPCR. State of Wyoming acquired a new stake in shares of Structure Therapeutics in the second quarter valued at about $28,000. Assetmark Inc. grew its holdings in Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after buying an additional 820 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Structure Therapeutics by 29.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock worth $92,000 after buying an additional 994 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Structure Therapeutics during the second quarter worth approximately $129,000. Finally, DNB Asset Management AS bought a new stake in shares of Structure Therapeutics in the second quarter valued at approximately $221,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Stock Up 5.4%

NASDAQ GPCR opened at $78.93 on Tuesday. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $13.22 and a twelve month high of $94.90. The stock has a market cap of $4.79 billion, a P/E ratio of -64.70 and a beta of -2.07. The company’s 50-day simple moving average is $71.70 and its 200 day simple moving average is $41.82.

Analysts Set New Price Targets

GPCR has been the topic of a number of research reports. Citizens Jmp boosted their target price on shares of Structure Therapeutics from $87.00 to $120.00 and gave the stock a “market outperform” rating in a research report on Friday, December 12th. The Goldman Sachs Group upgraded shares of Structure Therapeutics to a “strong-buy” rating in a report on Tuesday, January 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. Jefferies Financial Group set a $125.00 price target on Structure Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 11th. Finally, Morgan Stanley upped their price target on Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $104.45.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.